Q4 2020 Coherus BioSciences Inc Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter and Full Year 2020 Coherus BioSciences Conference Call. (Operator Instructions)
I would now like to turn the conference over to your host today, Mr. McDavid Stilwell. Sir, please go ahead.
Thank you. Good afternoon, everyone, and thank you for joining us. We issued a press release earlier announcing our 2020 fiscal year and fourth quarter results and the release can be found on the Coherus BioSciences website.
Today's call includes forward-looking statements regarding Coherus' current expectations. These statements include, but are not limited to, our ability to advance our biosimilar and immuno-oncology product candidates through development and registration. Our commercialization of UDENYCA and other potential products in the future, our ability to meet our R&D and SG&A expense guidance for 2021 as well as our uses of capital, all of which involve
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |